Prime time for immune-checkpoint targeted therapy at ASCO 2015

Aurélien Marabelle; Bertrand Routy; Judith Michels; Guido Kroemer; Laurence Zitvogel

doi:10.1080/2162402X.2015.1068494

Prime time for immune-checkpoint targeted therapy at ASCO 2015

Aurélien Marabelle, Bertrand Routy, Judith Michels, Guido Kroemer, Laurence Zitvogel

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

ABSTRACT: Cancer immunotherapy has been one of the dominant topics in oral presentations and abstracts during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). The renewed interest in immunotherapy is explained by the wide spectrum of activity, the durability of tumor responses and the rapid clinical development of immune-checkpoint targeted monoclonal antibodies. These new drugs are currently revolutionizing the field of oncology. Here we highlight what were to us the most important results announced during the annual meeting of ASCO held in Chicago, IL from May, 29th to June, 2nd 2015. In addition, we searched all the posters/published abstracts pertinent to the field of immunooncology from this year conference. Among more than 400 published abstracts on this topic, we have grouped and briefly summarized the most relevant ones.

Original language	English
Journal	OncoImmunology
Volume	5
Issue number	3
DOIs	https://doi.org/10.1080/2162402X.2015.1068494
Publication status	Published - 3 Mar 2016

Access to Document

10.1080/2162402X.2015.1068494

Cite this

@article{40a781f91a5c402aab385535fba269a8,

title = "Prime time for immune-checkpoint targeted therapy at ASCO 2015",

abstract = "ABSTRACT: Cancer immunotherapy has been one of the dominant topics in oral presentations and abstracts during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). The renewed interest in immunotherapy is explained by the wide spectrum of activity, the durability of tumor responses and the rapid clinical development of immune-checkpoint targeted monoclonal antibodies. These new drugs are currently revolutionizing the field of oncology. Here we highlight what were to us the most important results announced during the annual meeting of ASCO held in Chicago, IL from May, 29th to June, 2nd 2015. In addition, we searched all the posters/published abstracts pertinent to the field of immunooncology from this year conference. Among more than 400 published abstracts on this topic, we have grouped and briefly summarized the most relevant ones.",

author = "Aur{\'e}lien Marabelle and Bertrand Routy and Judith Michels and Guido Kroemer and Laurence Zitvogel",

note = "Publisher Copyright: {\textcopyright} 2016, {\textcopyright} Taylor & Francis Group, LLC.",

year = "2016",

month = mar,

day = "3",

doi = "10.1080/2162402X.2015.1068494",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

number = "3",

}

TY - JOUR

T1 - Prime time for immune-checkpoint targeted therapy at ASCO 2015

AU - Marabelle, Aurélien

AU - Routy, Bertrand

AU - Michels, Judith

AU - Kroemer, Guido

AU - Zitvogel, Laurence

PY - 2016/3/3

Y1 - 2016/3/3

N2 - ABSTRACT: Cancer immunotherapy has been one of the dominant topics in oral presentations and abstracts during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). The renewed interest in immunotherapy is explained by the wide spectrum of activity, the durability of tumor responses and the rapid clinical development of immune-checkpoint targeted monoclonal antibodies. These new drugs are currently revolutionizing the field of oncology. Here we highlight what were to us the most important results announced during the annual meeting of ASCO held in Chicago, IL from May, 29th to June, 2nd 2015. In addition, we searched all the posters/published abstracts pertinent to the field of immunooncology from this year conference. Among more than 400 published abstracts on this topic, we have grouped and briefly summarized the most relevant ones.

AB - ABSTRACT: Cancer immunotherapy has been one of the dominant topics in oral presentations and abstracts during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). The renewed interest in immunotherapy is explained by the wide spectrum of activity, the durability of tumor responses and the rapid clinical development of immune-checkpoint targeted monoclonal antibodies. These new drugs are currently revolutionizing the field of oncology. Here we highlight what were to us the most important results announced during the annual meeting of ASCO held in Chicago, IL from May, 29th to June, 2nd 2015. In addition, we searched all the posters/published abstracts pertinent to the field of immunooncology from this year conference. Among more than 400 published abstracts on this topic, we have grouped and briefly summarized the most relevant ones.

UR - http://www.scopus.com/inward/record.url?scp=84961588772&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1068494

DO - 10.1080/2162402X.2015.1068494

M3 - Review article

AN - SCOPUS:84961588772

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 3

ER -

Prime time for immune-checkpoint targeted therapy at ASCO 2015

Abstract

Access to Document

Other files and links

Cite this